Skip to main content
Erschienen in: Supportive Care in Cancer 12/2008

01.12.2008 | Original Article

Functional evaluation of conventional ‘Celsite®’ venous ports versus ‘Vortex®’ ports with a tangential outlet: a prospective randomised pilot study

verfasst von: G. A. Goossens, G. Verbeeck, P. Moons, W. Sermeus, I. De Wever, M. Stas

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2008

Einloggen, um Zugang zu erhalten

Abstract

Goal of work

Totally implantable venous access ports are widely accepted in cancer patient treatment, but withdrawal occlusion (WO) can hamper the use of the device. A newly designed Vortex® VX port, with a tangential outlet, should allow better clearance of the chamber, thereby reducing occlusion of the device. The present study compared the Vortex® port to the classically shaped Celsite® port with regards to functional complications.

Materials and methods

Two hundred cancer patients were included in a prospective, randomised controlled trial and randomly assigned to the implantation of a Vortex® or a Celsite® port. Insertion details such as used vein, catheter tip position and infusion or aspiration abilities were recorded. Data were collected concerning ease of access, and functional evaluation was performed each time the port was accessed, regarding the ability to infuse fluids with a syringe and to withdraw blood by measuring the filling time of a Vacutainer® blood tube.

Main results

Ninety-nine patients received a Celsite® port, and 101 had a Vortex® port. Demographic variables and insertion details were comparable in both groups. All functional complications, including WO, total occlusion, sluggish inflow and sluggish withdrawal, were higher in the Celsite® group (16.12%) than in the Vortex® group (11.36%). This difference was not statistically significant.

Conclusions

This study revealed that functional problems occurred less frequently in Vortex® compared to Celsite® ports. Differences were small and not significant, which indicates that functional problems may be related to other factors.
Literatur
1.
Zurück zum Zitat Biffi R, De BF, Orsi F, Pozzi S, Arnaldi P, Goldhirsch A, Rotmensz N, Robertson C, Bellomi M, Andreoni B (2001) A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 92:1204–1212PubMedCrossRef Biffi R, De BF, Orsi F, Pozzi S, Arnaldi P, Goldhirsch A, Rotmensz N, Robertson C, Bellomi M, Andreoni B (2001) A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 92:1204–1212PubMedCrossRef
2.
Zurück zum Zitat Caers J, Fontaine C, Vinh-Hung V, De Mey J, Ponnet G, Oost C, Lamote J, De Greve J, Van Camp B, Lacor P (2005) Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports. Support Care Cancer 13:325–331PubMedCrossRef Caers J, Fontaine C, Vinh-Hung V, De Mey J, Ponnet G, Oost C, Lamote J, De Greve J, Van Camp B, Lacor P (2005) Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports. Support Care Cancer 13:325–331PubMedCrossRef
3.
Zurück zum Zitat Carlo JT, Lamont JP, McCarty TM, Livingston S, Kuhn JA (2004) A prospective randomized trial demonstrating valved implantable ports have fewer complications and lower overall cost than nonvalved implantable ports. Am J Surg 188:722–727PubMedCrossRef Carlo JT, Lamont JP, McCarty TM, Livingston S, Kuhn JA (2004) A prospective randomized trial demonstrating valved implantable ports have fewer complications and lower overall cost than nonvalved implantable ports. Am J Surg 188:722–727PubMedCrossRef
4.
Zurück zum Zitat Cohn DE, Mutch DG, Rader JS, Farrell M, Awantang R, Herzog TJ (2001) Factors predicting subcutaneous implanted central venous port function: the relationship between catheter tip location and port failure in patients with gynecologic malignancies. Gynecol Oncol 83:533–536PubMedCrossRef Cohn DE, Mutch DG, Rader JS, Farrell M, Awantang R, Herzog TJ (2001) Factors predicting subcutaneous implanted central venous port function: the relationship between catheter tip location and port failure in patients with gynecologic malignancies. Gynecol Oncol 83:533–536PubMedCrossRef
5.
Zurück zum Zitat Goossens GA, Vrebos M, De Wever I, Stas M (2004) Vacutainer filling time through subcutaneous venous access devices. J Vasc Access 5:154–160PubMed Goossens GA, Vrebos M, De Wever I, Stas M (2004) Vacutainer filling time through subcutaneous venous access devices. J Vasc Access 5:154–160PubMed
6.
Zurück zum Zitat Goossens L, Jérôme M, Stas M (2005) Verstopte poortkatheters: hoe vaak komt dit voor en wat doen verpleegkundigen hieraan? Oncologisch Tijdschrift 23:28–29 Goossens L, Jérôme M, Stas M (2005) Verstopte poortkatheters: hoe vaak komt dit voor en wat doen verpleegkundigen hieraan? Oncologisch Tijdschrift 23:28–29
7.
Zurück zum Zitat Goossens L, Vrebos M, Stas M, Rottiers L, Evers G (2004) De incidentie van verstopping, trombose, infectie en extravasatie bij subcutaan veneuze poortkatheters van oncologische patiënten in Vlaamse ziekenhuizen. Een eerste analyse. Oncologisch Tijdschrift 21:54–59 Goossens L, Vrebos M, Stas M, Rottiers L, Evers G (2004) De incidentie van verstopping, trombose, infectie en extravasatie bij subcutaan veneuze poortkatheters van oncologische patiënten in Vlaamse ziekenhuizen. Een eerste analyse. Oncologisch Tijdschrift 21:54–59
8.
Zurück zum Zitat Hou SM, Wang PC, Sung YC, Lee HH, Liu HT, Chen YH (2005) Comparisons of outcomes and survivals for two central venous access port systems. J Surg Oncol 91:61–66PubMedCrossRef Hou SM, Wang PC, Sung YC, Lee HH, Liu HT, Chen YH (2005) Comparisons of outcomes and survivals for two central venous access port systems. J Surg Oncol 91:61–66PubMedCrossRef
9.
Zurück zum Zitat Krug F, Psathakis D, Hirsch U, Bruch H (1999) The K-port concept: proposal for optimising a fully implantable port system. J Oncol Pharm Practice 5:67–74 Krug F, Psathakis D, Hirsch U, Bruch H (1999) The K-port concept: proposal for optimising a fully implantable port system. J Oncol Pharm Practice 5:67–74
10.
Zurück zum Zitat Lakdja F, Roubault N, Fonrouge JM (1999) [A new system for permanent venous access, Cathlink 20: prospective clinical study. 95 cases]. Pathol Biol (Paris) 47:273–278 Lakdja F, Roubault N, Fonrouge JM (1999) [A new system for permanent venous access, Cathlink 20: prospective clinical study. 95 cases]. Pathol Biol (Paris) 47:273–278
11.
Zurück zum Zitat Lamont JP, McCarty TM, Stephens JS, Smith BA, Carlo J, Livingston S, Kuhn JA (2003) A randomized trial of valved vs nonvalved implantable ports for vascular access. Proc Bayl Univ Med Cent 16:384–387PubMed Lamont JP, McCarty TM, Stephens JS, Smith BA, Carlo J, Livingston S, Kuhn JA (2003) A randomized trial of valved vs nonvalved implantable ports for vascular access. Proc Bayl Univ Med Cent 16:384–387PubMed
12.
Zurück zum Zitat Lundberg G, Wahlberg E, Rickberg A, Olofsson P (1995) PAS-Port: a new implantable vascular access device for arm placement: experiences from the first two years. Eur J Surg 161:323–326PubMed Lundberg G, Wahlberg E, Rickberg A, Olofsson P (1995) PAS-Port: a new implantable vascular access device for arm placement: experiences from the first two years. Eur J Surg 161:323–326PubMed
13.
Zurück zum Zitat Minassian VA, Sood AK, Lowe P, Sorosky JI, Al-Jurf AS, Buller RE (2000) Longterm central venous access in gynecologic cancer patients. J Am Coll Surg 191:403–409PubMedCrossRef Minassian VA, Sood AK, Lowe P, Sorosky JI, Al-Jurf AS, Buller RE (2000) Longterm central venous access in gynecologic cancer patients. J Am Coll Surg 191:403–409PubMedCrossRef
14.
Zurück zum Zitat Moll S, Kenyon P, Bertoli L, De MJ, Homesley H, Deitcher SR (2006) Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. J Clin Oncol 24:3056–3060PubMedCrossRef Moll S, Kenyon P, Bertoli L, De MJ, Homesley H, Deitcher SR (2006) Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. J Clin Oncol 24:3056–3060PubMedCrossRef
15.
Zurück zum Zitat Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E (1982) Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 92:706–712PubMed Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E (1982) Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 92:706–712PubMed
16.
Zurück zum Zitat Petersen J, Delaney JH, Brakstad MT, Rowbotham RK, Bagley CM Jr. (1999) Silicone venous access devices positioned with their tips high in the superior vena cava are more likely to malfunction. Am J Surg 178:38–41PubMedCrossRef Petersen J, Delaney JH, Brakstad MT, Rowbotham RK, Bagley CM Jr. (1999) Silicone venous access devices positioned with their tips high in the superior vena cava are more likely to malfunction. Am J Surg 178:38–41PubMedCrossRef
17.
Zurück zum Zitat Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER (2001) Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial—the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 12:951–955PubMedCrossRef Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER (2001) Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial—the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 12:951–955PubMedCrossRef
18.
Zurück zum Zitat Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO (1984) Hickman catheter infections in patients with malignancies. Medicine (Baltimore) 63:189–200 Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO (1984) Hickman catheter infections in patients with malignancies. Medicine (Baltimore) 63:189–200
19.
Zurück zum Zitat Raad II, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP (1994) The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 271:1014–1016PubMedCrossRef Raad II, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP (1994) The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 271:1014–1016PubMedCrossRef
20.
Zurück zum Zitat Schutz JC, Patel AA, Clark TW, Solomon JA, Freiman DB, Tuite CM, Mondschein JI, Soulen MC, Shlansky-Goldberg RD, Stavropoulos SW, Kwak A, Chittams JL, Trerotola SO (2004) Relationship between chest port catheter tip position and port malfunction after interventional radiologic placement. J Vasc Interv Radiol 15:581–587PubMed Schutz JC, Patel AA, Clark TW, Solomon JA, Freiman DB, Tuite CM, Mondschein JI, Soulen MC, Shlansky-Goldberg RD, Stavropoulos SW, Kwak A, Chittams JL, Trerotola SO (2004) Relationship between chest port catheter tip position and port malfunction after interventional radiologic placement. J Vasc Interv Radiol 15:581–587PubMed
21.
Zurück zum Zitat Semba CP, Deitcher SR, Li X, Resnansky L, Tu T, McCluskey ER (2002) Treatment of occluded central venous catheters with alteplase: results in 1,064 patients. J Vasc Interv Radiol 13:1199–1205PubMedCrossRef Semba CP, Deitcher SR, Li X, Resnansky L, Tu T, McCluskey ER (2002) Treatment of occluded central venous catheters with alteplase: results in 1,064 patients. J Vasc Interv Radiol 13:1199–1205PubMedCrossRef
22.
Zurück zum Zitat Stas M, Mulier S, Pattyn P, Vijgen J, De Wever I (2001) Peroperative intravasal electrographic control of catheter tip position in access ports placed by venous cut-down technique. Eur J Surg Oncol 27:316–320PubMedCrossRef Stas M, Mulier S, Pattyn P, Vijgen J, De Wever I (2001) Peroperative intravasal electrographic control of catheter tip position in access ports placed by venous cut-down technique. Eur J Surg Oncol 27:316–320PubMedCrossRef
23.
Zurück zum Zitat Stevens B, Barton SE, Brechbill M, Moenter S, Piel AL, Shankle D (2000) A randomized, prospective trial of conventional vascular ports vs. the vortex “clear-flow” reservoir port in adult oncology patients. J Vasc Access Devices 5(4):37–40 Stevens B, Barton SE, Brechbill M, Moenter S, Piel AL, Shankle D (2000) A randomized, prospective trial of conventional vascular ports vs. the vortex “clear-flow” reservoir port in adult oncology patients. J Vasc Access Devices 5(4):37–40
24.
Zurück zum Zitat Svoboda P, Barton RP, Barbarash OL, Butylin AA, Jacobs BR, Lata J, Haire WD, Jaff MR, Firszt CM, Mouginis TL, Schuerr DM, Schulz GA, Schwartz LB, El-Shahawy MA (2004) Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: a multiple-center, international trial. Crit Care Med 32:1990–1996PubMedCrossRef Svoboda P, Barton RP, Barbarash OL, Butylin AA, Jacobs BR, Lata J, Haire WD, Jaff MR, Firszt CM, Mouginis TL, Schuerr DM, Schulz GA, Schwartz LB, El-Shahawy MA (2004) Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: a multiple-center, international trial. Crit Care Med 32:1990–1996PubMedCrossRef
25.
Zurück zum Zitat Verhamme P, Goossens G, Maleux G, Collen D, Stas M (2007) A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion. J Thromb Thrombolysis 24:1–5PubMedCrossRef Verhamme P, Goossens G, Maleux G, Collen D, Stas M (2007) A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion. J Thromb Thrombolysis 24:1–5PubMedCrossRef
26.
Zurück zum Zitat Vesely TM (2003) Central venous catheter tip position: a continuing controversy. J Vasc Interv Radiol 14:527–534PubMed Vesely TM (2003) Central venous catheter tip position: a continuing controversy. J Vasc Interv Radiol 14:527–534PubMed
Metadaten
Titel
Functional evaluation of conventional ‘Celsite®’ venous ports versus ‘Vortex®’ ports with a tangential outlet: a prospective randomised pilot study
verfasst von
G. A. Goossens
G. Verbeeck
P. Moons
W. Sermeus
I. De Wever
M. Stas
Publikationsdatum
01.12.2008
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2008
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0436-y

Weitere Artikel der Ausgabe 12/2008

Supportive Care in Cancer 12/2008 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.